Management of STEMI during the COVID-19 pandemic: Lessons learned in 2020 to prepare for 2021

As the prevalence of asymptomatic COVID-19 continues to increase, there is an increasing possibility that patients with COVID-19 may presen with ST-segment elevation myocardial infarction (STEMI). With social distancing and restricted access to preventive healthcare and emergency services, the manag...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Vardhmaan, Gupta, Kartik, Bhatia, Kirtipal, Bansal, Agam, Arora, Sameer, Khandelwal, Akshay K., Rosenberg, Jonathan R., Levisay, Justin P., Tommaso, Carl L., Ricciardi, Mark J., Qamar, Arman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831899/
https://www.ncbi.nlm.nih.gov/pubmed/33338636
http://dx.doi.org/10.1016/j.tcm.2020.12.003
Descripción
Sumario:As the prevalence of asymptomatic COVID-19 continues to increase, there is an increasing possibility that patients with COVID-19 may presen with ST-segment elevation myocardial infarction (STEMI). With social distancing and restricted access to preventive healthcare and emergency services, the management of acute cardiac emergencies such as myocardial infarction has suffered collateral damage. Thus far, global trends suggest a decrease in STEMI activations with possible worse outcomes due to delayed presentation and management. In this review, we discuss the challenges to STEMI management in the COVID-19 era and provide potential solutions for adherence to evidence-based therapies as the pandemic progresses into the year 2021.

Ejemplares similares